The study examined the prevalence of prescription medications in jails and state prisons for individuals with chronic conditions, such as asthma, type 2 diabetes, hypertension, hepatitis B and C, HIV infection, depression, and severe mental illness, compared with the general population.
Incarcerated people are significantly less likely to be treated for chronic conditions, such as asthma, in which rates may be severely undertreated among the jail and prison population in the United States, according to one study.
“Our findings raise serious concerns about the access to and quality of pharmacologic care for very common chronic health conditions among the incarcerated,” said the study’s senior author G Caleb Alexander, MD, professor in the Department of Epidemiology at the Bloomberg School, in a statement.1 “We knew going in that the US incarcerated population has a higher prevalence of some chronic diseases. But we were really surprised by the extent of potential undertreatment that we identified.”
The results of this cross-sectional descriptive study were published in JAMA Health Forum.2
The aim of this study was to evaluate the prevalence of prescription medications in jails and state prisons for individuals with chronic conditions, such as asthma, type 2 diabetes, hypertension, hepatitis B and C, HIV infection, depression, and severe mental illness compared with the non-incarcerated population.
The researchers used national health survey data from 2018 to 2020 to estimate the prevalence of chronic conditions among recently incarcerated individuals, and a commercial prescription database used to estimate the distribution of medication among the jail and prison population.
As a result, the researchers estimated the proportion of medications being sent to incarcerated jails and prisons was much lower compared to the burden of disease among this population:
Additionally, the researchers found that the incarceration populations accounted for chronic conditions:
After adjusting for disease prevalence, the researchers found the burden of the disease was 5.5-fold for asthma, 2.9-fold for diabetes, 2.4-fold for hypertension, 2.9-fold for hepatitis B or C, 3.0-fold for HIV, 4.1-fold for depression, and 4.1-fold for severe mental illness among the incarcerated population compared with the non-incarcerated population.
The researchers attribute these findings to several problems within the US jail and prison system, including understaffing, underfunding, and poor-quality health care. Furthermore, lack of transparency from prison health care providers creates difficulty for furthering research.
“Health care provided in jails and prisons is provided by a patchwork of health care providers, most commonly private contractors who do not widely share information about the services they provide to incarcerated people,” said study co-author Brendan Saloner, PhD, an associate professor in the Bloomberg School’s Department of Health Policy and Management, in a statemen. “The lack of transparency means that advocates and policymakers have a very incomplete picture of the medicines that are available during a stay in jail or prison.”
Despite limitations, the researchers believe the results of the study show enough evidence to suggest that there is a gap in prescribing pharmacological treatments to individuals with chronic conditions who have been incarcerated. Furthermore, evidence of undertreatment needs to continue to be investigated as a serious public health concern.
References
1. JohnsHopkinsSPH. Analysis of health and prescription data suggests chronic health conditions in U.S. incarcerated people may be severely undertreated. EurekAlert! https://www.eurekalert.org/news-releases/985864. Published April 14, 2023. Accessed April 24, 2023.
2. Curran J, Saloner B, Winkelman TNA, Alexander GC. Estimated use of prescription medications among individuals incarcerated in jails and state prisons in the US. JAMA Health Forum. 2023;4(4). doi:10.1001/jamahealthforum.2023.0482
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions
August 13th 2025More than 8 in 10 patients with rheumatoid arthritis were taking 5 or more medications at once, a practice linked to older age, multiple comorbidities, and more than 2000 potential drug-to-drug interactions.
Read More